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Purpose/Objective: Acuros is a new dose calculation 
algorithm implemented in the Eclipse TPS. It is a grid based 
Boltzmann solver that deterministically solves the linear 
Boltzmann transport equation. The accuracy of Acuros dose 
calculations has been shown to agree significantly better with 
Monte Carlo calculations than the Analytical Anisotropic 
Algorithm (AAA) in heterogeneous media.1 
The aim of this study was to assess the clinical impact of 
dose calculation with Acuros (reporting dose to medium) 
compared to AAA and PBC for a range of clinical treatment 
sites. 
Materials and Methods: Ten plans for each of the following 
sites were calculated in Eclipse 11.0.31 for PBC, AAA and 
Acuros; lung, breast, gynaecological, head and neck IMRT and 
prostate and pelvic node (PPN) VMAT. Acuros plans were 
calculated with heterogeneity on and reporting dose to 
medium using the 11.0 material table. The field parameters 
were maintained for all three algorithms and doses were 
calculated without fixing the number of MUs. Breast, lung 
and gynaecological plans were normalised to the isocentre or 
a reference point in soft tissue. IMRT and VMAT plans were 
normalised to give the prescription dose to the median of the 
planned primary PTV. The number of MUs, PTV coverage and 
organ at risk (OAR) doses were recorded. 
Results: The table below shows the mean percentage 
difference in MUs between the different algorithms.  
 
 
All Acuros plans displayed a reduction in the 95% PTV 
coverage compared to PBC; with average absolute reductions 
of 3.0% for breast, 1% for gynaecological, 2.5% for lung and 
1.7% for head and neck IMRT. 
Acuros lung and breast plans show a higher PTV coverage 
(4.3% higher for lung and 4.6% higher for breast) than AAA 
plans due to dose inaccuracies of the AAA algorithm in lung. 
Acuros head and neck IMRT plans displayed an average of 
0.7Gy increase in spinal cord dose and 1Gy increase in 
parotid dose compared to PBC. All OAR tolerances were still 
met without reoptimisation for the Acuros and AAA plans with 
the exception of the spinal cord PRV 1cc dose constraint for 3 
out of 10 of the patients. All OAR tolerances were met for 
the Acuros PPN VMAT plans.  
Conclusions: Plans calculated with Acuros exhibit higher 
point doses, under coverage in areas of low density and an 
increase in the number of MUs required to deliver the 
prescribed dose compared to PBC. Moving from AAA to Acuros 
would result in a 1.7-3% increase in MUs to deliver standard 
prescription doses and the increase in MUs would be larger at 
2-4.5% if moving from PBC to Acuros. This raises the question 
of whether dose prescriptions should change to remain 
consistent with current clinical practice or whether the 
change in physical dose delivered should be accepted. 
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Purpose/Objective: Whole breast radiotherapy with a boost 
to the tumour bed volume is standard treatment following 
breast conservation surgery for patients at high risk of 
tumour recurrence. At our institution clips inserted at surgery 
define the position of the tumour bed. Methods employed to 
treat this volume include electron fields, tangent photon 
fields, fixed field IMRT or VMAT. A planning study was 
undertaken to quantitatively compare the dose distributions 
obtained from 2 of these techniques, tangent photon fields 
and VMAT, in order to determine a standard treatment 
protocol for our patients. 
Materials and Methods: Treatment plans were prepared on 
suitable CT datasets for 40Gy in 15# to the whole breast 
(PTVWB) and 9Gy in 3# synchronous boost to the tumour bed 
volume (PTVTB) planned with both partial tangent fields and 
VMAT. Analysis of the resulting dose distributions within the 
summed plans included homogeneity index, conformity index 
and organ at risk (OAR) doses to highlight any significant 
differences between the two planning methods for the boost 
volume. 
Results: Creation of the whole breast plans followed our 
standard tangential planning technique, optimising to meet 
pre-defined dose volume constraints to PTVWB. Tangent fields 
for PTVTB were conformed with MLC field shaping. VMAT plans 
comprised 2 partial arcs extending no further than the gantry 
angles of the tangent fields. Plans were created for 5 right 
breasts and 10 left breasts. Mean volumes of PTVTB were 
65.7cc (right) (range 47.5-80.0cc) and 81.1cc (left) (52.5-
145.4cc). There was a slight improvement in homogeneity 
index (HI) for PTVWB with VMAT but no significant change for 
PTVTB. Conformity index (CI) for PTVTB was significantly 
improved with VMAT. OAR doses were analysed in relation to 
constraints used in the UK Intensity Modulated and Partial 
Organ Radiotherapy Trial – HIGHer-risk patient group (IMPORT 
HIGH). For right breasts all plans met the optimal 
constraints. For left breasts all plans met the mandatory 
constraints and all tangent plans met the optimal constraints. 
All VMAT plans met optimal constraints for all OARs other 
than the contra-lateral breast where mean dose was slightly 
higher than optimal in 2/10 VMAT plans. In general heart 
